Carvedilol
As of the edition of 20 October 2026, Carvedilol is a small molecule: marketed, first approved in 1991 (FR); acts on ADRA1A, ADRA1B and ADRA1D and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1995
- Kind
- Small molecule
- Brand name
- Coreg
- First approved
- 30 August 1991 (FR)
- Approvals on record
- 11 in 4 regions
- Holder of the most recent approval
- Waylis Therapeutics; 4 holders in all
- Registered trials
- 145, 19 stopped early
- Disease areas
- Heart and blood vessels; Digestive system; Cancer; Nutrition and metabolism; Lungs and airways; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Carvedilol.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 35 | 16 | 9 | 1 |
| Phase 1 | 29 | 24 | 0 | 4 |
| Phase 2 | 20 | 7 | 3 | 8 |
| Phase 3 | 23 | 12 | 3 | 3 |
| Phase 4 | 38 | 14 | 4 | 3 |
| All trials | 145 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GSK | Applicant and Lead sponsor of trials | 1995 to now |
| Waylis Therapeutics | Acquired holder | 2024 to now |